Показано 0 из 0
Дата |
---|
06:54 |
17.05.2024 |
16.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
6.31
|
6.40
|
6.45
|
6.33
|
6.88
|
6.40
|
|
|
2 650 000.00
|
|
6.46
|
6.67
|
6.95
|
6.46
|
7.05
|
6.46
|
|
|
8 260 000.00
|
|
6.69
|
6.90
|
6.52
|
6.52
|
7.30
|
6.90
|
|
|
43 790 000.00
|
|
6.90
|
6.95
|
7.01
|
6.80
|
7.26
|
6.95
|
|
|
6 610 000.00
|
|
6.90
|
7.02
|
7.29
|
6.22
|
7.29
|
7.01
|
|
|
14 430 000.00
|
|
6.75
|
6.76
|
7.25
|
6.25
|
7.25
|
6.76
|
|
|
11 740 000.00
|
|
7.00
|
7.27
|
7.54
|
6.42
|
7.98
|
7.00
|
|
|
28 210 000.00
|
|
7.31
|
7.38
|
5.29
|
5.03
|
7.71
|
7.31
|
|
|
15 780 000.00
|
|
5.16
|
5.18
|
5.25
|
5.04
|
5.38
|
5.16
|
|
|
937 760.00
|
|
5.16
|
5.25
|
5.68
|
5.05
|
5.68
|
5.25
|
|
|
1 760 000.00
|
|
HighTide Therapeutics Inc is a company mainly engaged in the manufacture of original new drugs. The Company focuses on metabolic diseases, digestive system diseases and other fields. The Company develops treatments for non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) and other indications.